Media stories about Endo International PLC (NASDAQ:ENDP) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endo International PLC earned a news impact score of 0.11 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.1612743995268 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s analysis:

Shares of Endo International PLC (NASDAQ:ENDP) traded up 0.53% during midday trading on Friday, hitting $7.59. 8,959,667 shares of the stock traded hands. The firm’s 50-day moving average is $10.93 and its 200 day moving average is $11.55. The company’s market capitalization is $1.69 billion. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $24.93.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the business earned $0.86 EPS. Equities analysts forecast that Endo International PLC will post $3.51 earnings per share for the current year.

ENDP has been the subject of several analyst reports. Mizuho reissued a “buy” rating and set a $19.00 price target (up from $18.00) on shares of Endo International PLC in a report on Thursday, May 25th. Vetr raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 price target for the company in a report on Tuesday, May 9th. Deutsche Bank AG cut their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, July 7th. Morgan Stanley cut their price target on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, ValuEngine downgraded shares of Endo International PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $14.86.

TRADEMARK VIOLATION WARNING: “Endo International PLC (NASDAQ:ENDP) Earns Daily News Sentiment Rating of 0.11” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at

In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.50% of the stock is owned by company insiders.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Insider Buying and Selling by Quarter for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.